2Fitten LJ, Vellas B, Dubois B, et al. Alzheimer's disease. New Engl J Med, 2004, 351(6): 56-67.
3Farlow MR. NMDA-receptor antagonists: A new therapeutic approach for Alzheimer's disease. Geriatrics, 2004, 59(6): 22-27.
4American psychiatric association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: American Psychiatric Press, 1994: 147-154.
5Iadad AR, Moore RA, Corral D. Assessing the quality of the reports of randomized clinical trials :is blinding necessary Control Clin Trials, 1996, 17(1): 1-12.
6Reisberg B, Doody R, Steffler A, et al. Memantine in moderate-tosevere Alzheimer's disease. N Engl J Med, 2003, 348(14): l333-l341.
7Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil:a randomized controlled trial. JAMA, 2004, 291(3): 317-324.
8Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry, 2006, 14(8): 704-715.
9van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord, 2007, 21(2): 136-143.
10Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results ofa randomised, double-blind, placebo-controlled 6-month study. J Alzheirners Dis, 2008, 13(1): 97- 107.
